{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:28:56Z","timestamp":1791325736986,"version":"4.3.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["17115015"],"award-info":[{"award-number":["17115015"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["17121214"],"award-info":[{"award-number":["17121214"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["17126317"],"award-info":[{"award-number":["17126317"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["17122519"],"award-info":[{"award-number":["17122519"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Influenza epidemics and pandemics are constant threats to global public health. Although strategies including vaccines and antiviral drugs have achieved great advances in controlling influenza virus infection, the efficacy of these strategies is limited by the highly frequent mutations in the viral genome and the emergence of drug-resistant strains. Our previous study indicated that boosting the immunity of human V\u03b39V\u03b42-T cells with the phosphoantigen pamidronate could be a therapeutic strategy to treat seasonal and avian influenza virus infections. However, one notable drawback of \u03b3\u03b4-T cell-based immunotherapy is the rapid exhaustion of proliferation and effector responses due to repeated treatments with phosphoantigens. Here, we found that the expression of CD137 was inducible in V\u03b39V\u03b42-T cells following antigenic stimulation. CD137<jats:sup>+<\/jats:sup> V\u03b39V\u03b42-T cells displayed more potent antiviral activity against influenza virus than their CD137<jats:sup>\u2212<\/jats:sup> counterparts in vitro and in Rag2<jats:sup>-\/-<\/jats:sup> \u03b3c<jats:sup>-\/-<\/jats:sup> mice. We further demonstrated that CD137 costimulation was essential for V\u03b39V\u03b42-T cell activation, proliferation, survival and effector functions. In humanized mice reconstituted with human peripheral blood mononuclear cells, CD137 costimulation with a recombinant human CD137L protein boosted the therapeutic effects of pamidronate against influenza virus. Our study provides a novel strategy of targeting CD137 to improve the efficacy of V\u03b39V\u03b42-T cell-based immunotherapy.<\/jats:p>","DOI":"10.1038\/s41392-020-0174-2","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T23:05:32Z","timestamp":1591139132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["CD137 costimulation enhances the antiviral activity of V\u03b39V\u03b42-T cells against influenza virus"],"prefix":"10.1038","volume":"5","author":[{"given":"Yujun","family":"Pei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"174_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/emph\/eoy013","volume":"2018","author":"ES Bailey","year":"2018","unstructured":"Bailey, E. S. et al. The continual threat of influenza virus infections at the human\u2013animal interface: what is new from a one health perspective? Evol. Med. Public Health 2018, 192\u2013198 (2018).","journal-title":"Evol. Med. Public Health"},{"key":"174_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/irv.12570","volume":"12","author":"T Ziegler","year":"2018","unstructured":"Ziegler, T., Mamahit, A. & Cox, N. J. 65 years of influenza surveillance by a World Health Organization-coordinated global network. Influenza Other Respir. Viruses 12, 558\u2013565 (2018).","journal-title":"Influenza Other Respir. Viruses"},{"key":"174_CR3","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1586\/erv.12.63","volume":"11","author":"T Rebmann","year":"2012","unstructured":"Rebmann, T. & Zelicoff, A. Vaccination against influenza: role and limitations in pandemic intervention plans. Expert Rev. Vaccines 11, 1009\u20131019 (2012).","journal-title":"Expert Rev. Vaccines"},{"key":"174_CR4","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1002\/eji.200939911","volume":"39","author":"JSM Peiris","year":"2009","unstructured":"Peiris, J. S. M., Tu, W.-w & Yen, H.-l A novel H1N1 virus causes the first pandemic of the 21st century. Eur. J. Immunol. 39, 2946\u20132954 (2009).","journal-title":"Eur. J. Immunol."},{"key":"174_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/irv.12047","volume":"7","author":"JL McKimm-Breschkin","year":"2013","unstructured":"McKimm-Breschkin, J. L. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir. Viruses 7, 25\u201336 (2013).","journal-title":"Influenza Other Respir. Viruses"},{"key":"174_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1473-3099(16)30465-0","volume":"17","author":"K Leung","year":"2017","unstructured":"Leung, K., Lipsitch, M., Yuen, K. Y. & Wu, J. T. Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study. Lancet Infec. Dis. 17, 339\u2013347 (2017).","journal-title":"Lancet Infec. Dis."},{"key":"174_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/IDR.S105473","volume":"10","author":"M Hussain","year":"2017","unstructured":"Hussain, M. et al. Drug resistance in influenza A virus: the epidemiology and management. Infect. Drug Resist. 10, 121\u2013134 (2017).","journal-title":"Infect. Drug Resist."},{"key":"174_CR8","doi-asserted-by":"publisher","first-page":"101300","DOI":"10.1016\/j.smim.2019.101300","volume":"43","author":"BX Wang","year":"2019","unstructured":"Wang, B. X. & Fish, E. N. Global virus outbreaks: Interferons as 1st responders. Semin. Immunol. 43, 101300 (2019).","journal-title":"Semin. Immunol."},{"key":"174_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/cmi.2012.43","volume":"10","author":"J Zheng","year":"2013","unstructured":"Zheng, J., Liu, Y., Lau, Y. L. & Tu, W. gammadelta-T cells: an unpolished sword in human anti-infection immunity. Cell Mol. Immunol. 10, 50\u201357 (2013).","journal-title":"Cell Mol. Immunol."},{"key":"174_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/cmi.2017.164","volume":"16","author":"Y Zhu","year":"2019","unstructured":"Zhu, Y. et al. miR-125b-5p and miR-99a-5p downregulate human gammadelta T-cell activation and cytotoxicity. Cell Mol. Immunol. 16, 112\u2013125 (2019).","journal-title":"Cell Mol. Immunol."},{"key":"174_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2781","volume":"10","author":"M Bonneville","year":"2010","unstructured":"Bonneville, M., O\u2019Brien, R. L. & Born, W. K. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10, 467\u2013478 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"174_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coi.2005.11.007","volume":"18","author":"WK Born","year":"2006","unstructured":"Born, W. K., Reardon, C. L. & O\u2019Brien, R. L. The function of gammadelta T cells in innate immunity. Curr. Opin. Immunol. 18, 31\u201338 (2006).","journal-title":"Curr. Opin. Immunol."},{"key":"174_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.imbio.2007.10.006","volume":"213","author":"S Beetz","year":"2008","unstructured":"Beetz, S. et al. Innate immune functions of human gammadelta T cells. Immunobiology 213, 173\u2013182 (2008).","journal-title":"Immunobiology"},{"key":"174_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.coi.2006.07.002","volume":"18","author":"M Bonneville","year":"2006","unstructured":"Bonneville, M. & Scotet, E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 18, 539\u2013546 (2006).","journal-title":"Curr. Opin. Immunol."},{"key":"174_CR15","doi-asserted-by":"publisher","first-page":"732893","DOI":"10.1155\/2010\/732893","volume":"2010","author":"EM Urban","year":"2010","unstructured":"Urban, E. M., Chapoval Ai Fau - Pauza, C. D. & Pauza, C. D. Repertoire development and the control of cytotoxic\/effector function in human gammadelta T cells. Clin. Dev. Immunol. 2010, 732893 (2010).","journal-title":"Clin. Dev. Immunol."},{"key":"174_CR16","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1086\/605413","volume":"200","author":"G Qin","year":"2009","unstructured":"Qin, G. et al. Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J. Infect. Dis. 200, 858\u2013865 (2009).","journal-title":"J. Infect. Dis."},{"key":"174_CR17","doi-asserted-by":"publisher","first-page":"10109","DOI":"10.1128\/JVI.05341-11","volume":"85","author":"G Qin","year":"2011","unstructured":"Qin, G. et al. Type 1 responses of human Vgamma9Vdelta2 T cells to influenza A viruses. J. Virol. 85, 10109\u201310116 (2011).","journal-title":"J. Virol."},{"key":"174_CR18","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/infdis\/jis253","volume":"205","author":"G Qin","year":"2012","unstructured":"Qin, G. et al. Phenotypic and functional characterization of human gammadelta T-cell subsets in response to influenza A viruses. J. Infect. Dis. 205, 1646\u20131653 (2012).","journal-title":"J. Infect. Dis."},{"key":"174_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/cmi.2012.70","volume":"10","author":"H Li","year":"2013","unstructured":"Li, H. et al. Human Vgamma9Vdelta2-T cells efficiently kill influenza virus-infected lung alveolar epithelial cells. Cell Mol. Immunol. 10, 159\u2013164 (2013).","journal-title":"Cell Mol. Immunol."},{"key":"174_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3389\/fimmu.2018.00599","volume":"9","author":"Q Chen","year":"2018","unstructured":"Chen, Q. et al. Human Vgamma9Vdelta2-T cells synergize CD4(+) T follicular helper cells to produce influenza virus-specific antibody. Front. Immunol. 9, 599 (2018).","journal-title":"Front. Immunol."},{"key":"174_CR21","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1084\/jem.20110226","volume":"208","author":"W Tu","year":"2011","unstructured":"Tu, W. et al. The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice. J. Exp. Med. 208, 1511\u20131522 (2011).","journal-title":"J. Exp. Med."},{"key":"174_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135999","volume":"10","author":"J Zheng","year":"2015","unstructured":"Zheng, J. et al. The therapeutic effect of pamidronate on lethal avian influenza A H7N9 virus infected humanized mice. PLoS ONE 10, e0135999 (2015).","journal-title":"PLoS ONE"},{"key":"174_CR23","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.4049\/jimmunol.175.8.5471","volume":"175","author":"H Sicard","year":"2005","unstructured":"Sicard, H. et al. In vivo immunomanipulation of V\u03b39V\u03b42 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J. Immunol. 175, 5471\u20135480 (2005).","journal-title":"J. Immunol."},{"key":"174_CR24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00262-016-1829-2","volume":"65","author":"C Chester","year":"2016","unstructured":"Chester, C., Ambulkar, S. & Kohrt, H. E. 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol. Immunother. 65, 1243\u20131248 (2016).","journal-title":"Cancer Immunol. Immunother."},{"key":"174_CR25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nm1405","volume":"12","author":"T Uno","year":"2006","unstructured":"Uno, T. et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12, 693\u2013698 (2006).","journal-title":"Nat. Med."},{"key":"174_CR26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nm0697-682","volume":"3","author":"I Melero","year":"1997","unstructured":"Melero, I. et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3, 682\u2013685 (1997).","journal-title":"Nat. Med."},{"key":"174_CR27","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Shao, Q. & Peng, G. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cell Mol. Immunol. 17, 27\u201335 (2020).","DOI":"10.1038\/s41423-019-0344-8"},{"key":"174_CR28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/ni798","volume":"3","author":"ES Halstead","year":"2002","unstructured":"Halstead, E. S., Mueller Ym Fau - Altman, J. D., Altman Jd Fau - Katsikis, P. D. & Katsikis, P. D. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat. Immunol. 3, 536\u2013541 (2002).","journal-title":"Nat. Immunol."},{"key":"174_CR29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1365-2567.2004.01917.x","volume":"112","author":"MW Munks","year":"2004","unstructured":"Munks, M. W. et al. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology 112, 559\u2013566 (2004).","journal-title":"Immunology"},{"key":"174_CR30","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/nm942","volume":"9","author":"V Rubio","year":"2003","unstructured":"Rubio, V. et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9, 1377\u20131382 (2003).","journal-title":"Nat. Med."},{"key":"174_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ccr.2014.07.026","volume":"26","author":"Z Xiang","year":"2014","unstructured":"Xiang, Z. et al. Targeted activation of human Vgamma9Vdelta2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease. Cancer Cell. 26, 565\u2013576 (2014).","journal-title":"Cancer Cell."},{"key":"174_CR32","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1165\/rcmb.2017-0326OC","volume":"58","author":"K Ni","year":"2018","unstructured":"Ni, K. et al. PD-1\/PD-L1 Pathway mediates the alleviation of pulmonary fibrosis by human mesenchymal stem cells in humanized mice. Am. J. Respir. Cell Mol. Biol. 58, 684\u2013695 (2018).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"174_CR33","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.4049\/jimmunol.168.8.3777","volume":"168","author":"EM Bertram","year":"2002","unstructured":"Bertram, E. M., Lau P Fau - Watts, T. H. & Watts, T. H. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J. Immunol. 168, 3777\u20133785 (2002).","journal-title":"J. Immunol."},{"key":"174_CR34","doi-asserted-by":"publisher","first-page":"934","DOI":"10.4049\/jimmunol.182.2.934","volume":"182","author":"GH Lin","year":"2009","unstructured":"Lin, G. H. et al. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J. Immunol. 182, 934\u2013947 (2009).","journal-title":"J. Immunol."},{"key":"174_CR35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3389\/fimmu.2012.00332","volume":"3","author":"Y Zhao","year":"2012","unstructured":"Zhao, Y., Tahiliani, V., Salek-Ardakani, S. & Croft, M. Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens. Front. Immunol. 3, 332 (2012).","journal-title":"Front. Immunol."},{"key":"174_CR36","doi-asserted-by":"publisher","first-page":"47 LP-47 55","DOI":"10.1084\/jem.186.1.47","volume":"186","author":"WW Shuford","year":"1997","unstructured":"Shuford, W. W. et al. 4-1BB costimulatory signals preferentially induce CD8+ T\u2002cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186, 47 LP-47 55 (1997).","journal-title":"J. Exp. Med."},{"key":"174_CR37","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/eji.201242842","volume":"43","author":"SJ Lee","year":"2013","unstructured":"Lee, S. J. et al. 4\u20131BB signal stimulates the activation, expansion, and effector functions of \u03b3\u03b4 T cells in mice and humans. Eur. J. Immunol. 43, 1839\u20131848 (2013).","journal-title":"Eur. J. Immunol."},{"key":"174_CR38","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.4049\/jimmunol.1201854","volume":"190","author":"GH Lin","year":"2013","unstructured":"Lin, G. H. et al. GITR-dependent regulation of 4-1BB expression: implications for T cell memory and anti-4-1BB-induced pathology. J. Immunol. 190, 4627\u20134639 (2013).","journal-title":"J. Immunol."},{"key":"174_CR39","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1053\/j.seminoncol.2010.09.008","volume":"37","author":"PA Ascierto","year":"2010","unstructured":"Ascierto, P. A. et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37, 508\u2013516 (2010).","journal-title":"Semin. Oncol."},{"key":"174_CR40","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/0008-5472.CAN-18-2401","volume":"79","author":"HB Barsoumian","year":"2019","unstructured":"Barsoumian, H. B. et al. A novel form of 4-1BBL prevents cancer development via nonspecific activation of CD4(+) T and natural killer cells. Cancer Res. 79, 783\u2013794 (2019).","journal-title":"Cancer Res."},{"key":"174_CR41","doi-asserted-by":"publisher","first-page":"6441","DOI":"10.1158\/0008-5472.CAN-14-1768-A","volume":"74","author":"AK Srivastava","year":"2014","unstructured":"Srivastava, A. K. et al. SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res. 74, 6441\u20136451 (2014).","journal-title":"Cancer Res."},{"key":"174_CR42","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","volume":"67","author":"F Dieli","year":"2007","unstructured":"Dieli, F. et al. Targeting human \u03b3\u03b4 T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450 (2007).","journal-title":"Cancer Res."},{"key":"174_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/bjh.12090","volume":"160","author":"MS Braza","year":"2013","unstructured":"Braza, M. S. & Klein, B. Anti-tumour immunotherapy with V\u03b39V\u03b42 T lymphocytes: from the bench to the bedside. Br. J. Haematol. 160, 123\u2013132 (2013).","journal-title":"Br. J. Haematol."},{"issue":"5","key":"174_CR44","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41423-019-0247-8","volume":"17","author":"L\u00e9once Kouakanou","year":"2019","unstructured":"Kouakanou, L. et al. Vitamin C promotes the proliferation and effector functions of human gammadelta T cells. Cell Mol. Immunol. https:\/\/doi.org\/10.1038\/s41423-019-0247-8 (2019)","journal-title":"Cellular & Molecular Immunology"},{"key":"174_CR45","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/cmi.2017.10","volume":"15","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Uncompromised NK cell activation is essential for virus-specific CTL activity during acute influenza virus infection. Cell Mol. Immunol. 15, 827\u2013837 (2018).","journal-title":"Cell Mol. Immunol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0174-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T13:45:57Z","timestamp":1670247957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0174-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1038\/s41392-020-0174-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"assertion":[{"value":"30 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}